Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L B Grochow

Showing results (31-40 of 85) with videos related to

Pageof 9
Sort By:
Cancer Treatment Reports|November 1, 1985
Tastes associated with parenteral chemotherapy for breast cancerJ H Fetting, P M Wilcox, V R Sheidler, et al.
Journal of the National Cancer Institute|July 6, 1988
Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activityE K Rowinsky, D A Noe, D W Orr, et al.
Blood|November 11, 1992
Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalationA M Yeager, J E Wagner, M L Graham, et al.
Cancer|April 15, 1984
Acute anthracycline cardiotoxicity. Comparative morphologic study of three analoguesA L Taylor, M M Applefeld, P H Wiernik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1993
Regional chemotherapy devices: effect of experience and anatomy on complicationsK A Campbell, R C Burns, J V Sitzmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1986
Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancerE K Rowinsky, D S Ettinger, L B Grochow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumorsE K Rowinsky, L B Grochow, S E Sartorius, et al.
Cancer Research|November 15, 1992
Intrathecal 4-hydroperoxycyclophosphamide: neurotoxicity, cerebrospinal fluid pharmacokinetics, and antitumor activity in a rabbit model of VX2 leptomeningeal carcinomatosisP C Phillips, T T Than, L C Cork, et al.
Cancer Chemotherapy and Pharmacology|July 8, 1998
Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor TherapyS A Grossman, F Hochberg, J Fisher, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic dataJ M Borkowski, M Duerr, R C Donehower, et al.
Pageof 9

Showing results (31-40 of 85) with videos related to

Sort By:
Pageof 9
Cancer Treatment Reports|November 1, 1985
Tastes associated with parenteral chemotherapy for breast cancerJ H Fetting, P M Wilcox, V R Sheidler, et al.
Journal of the National Cancer Institute|July 6, 1988
Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activityE K Rowinsky, D A Noe, D W Orr, et al.
Blood|November 11, 1992
Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalationA M Yeager, J E Wagner, M L Graham, et al.
Cancer|April 15, 1984
Acute anthracycline cardiotoxicity. Comparative morphologic study of three analoguesA L Taylor, M M Applefeld, P H Wiernik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1993
Regional chemotherapy devices: effect of experience and anatomy on complicationsK A Campbell, R C Burns, J V Sitzmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1986
Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancerE K Rowinsky, D S Ettinger, L B Grochow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumorsE K Rowinsky, L B Grochow, S E Sartorius, et al.
Cancer Research|November 15, 1992
Intrathecal 4-hydroperoxycyclophosphamide: neurotoxicity, cerebrospinal fluid pharmacokinetics, and antitumor activity in a rabbit model of VX2 leptomeningeal carcinomatosisP C Phillips, T T Than, L C Cork, et al.
Cancer Chemotherapy and Pharmacology|July 8, 1998
Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor TherapyS A Grossman, F Hochberg, J Fisher, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic dataJ M Borkowski, M Duerr, R C Donehower, et al.
Pageof 9